Annual percent changes in lymphoid neoplasm incidence rates*by subtype, race, and sex, 12 SEER registries, 1992-2001
. | . | Men . | . | . | Women . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm subtype . | Total† . | White . | Black . | Asian . | White . | Black . | Asian . | ||||
| Lymphoid neoplasms, total | –0.50‡ | –0.84§ | –1.84 | –0.33 | 0.08 | 0.14 | 1.39 | ||||
| B-cell lymphoid neoplasms, total | 0.51‡ | 0.23 | –1.25 | 0.86 | 1.01§ | 0.43 | 2.11‡ | ||||
| DLBCL | –0.46§ | –0.73§ | –2.28 | –1.99 | 0.19 | 1.27 | 1.75 | ||||
| Marginal zone lymphoma | 21.31§ | 21.36§ | –∥ | 18.14‡ | 22.17§ | –∥ | 17.49‡ | ||||
| Follicular lymphoma | 0.51 | 0.10 | –1.31 | 4.48 | 1.24‡ | 0.19 | –0.05 | ||||
| CLL/SLL | –2.67§ | –2.20§ | –3.68‡ | –0.76 | –3.11§ | –1.78 | –8.99§ | ||||
| Mantle cell lymphoma | 8.08§ | 12.21§ | 5.74 | 13.67‡ | 2.02 | –∥ | –∥ | ||||
| Burkitt lymphoma/leukemia | 8.36§ | 5.47‡ | 7.95 | 17.85§ | 15.61§ | –∥ | 11.48 | ||||
| Plasma cell neoplasms | –0.73 | –0.78 | –1.86 | –2.06 | –0.67 | –1.59 | 2.79 | ||||
| Hairy cell leukemia | –1.84 | –2.77‡ | –∥ | –1.13 | 2.35 | –∥ | –∥ | ||||
| Lymphoplasmacytic lymphoma | 4.42‡ | 5.30‡ | 5.41 | 5.25 | 2.86 | –5.31 | –∥ | ||||
| Waldenström macroglobulinemia | –0.21 | 1.01 | –3.25 | –6.51 | –1.11 | –∥ | –∥ | ||||
| B-cell lymphoid neoplasms, NOS | 1.64 | 1.36 | 3.48 | –1.34 | 2.13 | 7.53 | 0.92 | ||||
| T/NK-cell lymphoid neoplasms, total | 3.80§ | 3.45§ | 1.09 | 3.73‡ | 4.32 | 6.74‡ | 1.05 | ||||
| Mycosis fungoides/Sézary syndrome | 1.11 | 1.16 | –1.73 | –5.20 | 1.32 | 6.08 | –2.09 | ||||
| Peripheral T-cell lymphoma | 6.55§ | 6.21§ | 0.77 | 5.09 | 6.15‡ | 13.53‡ | 2.24 | ||||
| T/NK-cell lymphoid neoplasms, NOS | 3.26‡ | 3.01 | 4.46 | 7.32 | 4.52 | –0.69 | 3.05 | ||||
| Lymphoblastic leukemia/lymphoma | 0.08 | –0.82 | –4.03 | 0.94 | 2.24 | 2.17 | –1.90 | ||||
| Prolymphocytic leukemia | 3.93 | 0.73 | –∥ | –∥ | 3.26 | –∥ | –∥ | ||||
| Hodgkin lymphoma | –0.49 | –0.27 | 1.18 | –0.63 | –0.52 | –3.12 | 6.61‡ | ||||
| Classical Hodgkin lymphoma | –0.60‡ | –0.41 | 0.94 | –0.41 | –0.53 | –3.89‡ | 7.00‡ | ||||
| Nodular sclerosis | 0.17 | 0.66 | 3.67 | 0.67 | –0.32 | –2.65 | 5.64 | ||||
| Mixed cellularity/lymphocyte depleted | –6.02§ | –6.09§ | –6.54‡ | –8.15 | –4.09‡ | –11.27 | 2.76 | ||||
| Classical Hodgkin lymphoma, NOS | 3.52‡ | 3.96‡ | 6.24 | –∥ | 2.89 | –1.05 | –∥ | ||||
| Nodular lymphocyte predominant Hodgkin lymphoma | 3.20 | 4.00 | 5.06 | –∥ | 0.80 | 4.61 | –∥ | ||||
| Unknown type lymphoid neoplasms | –12.41§ | –13.86§ | –11.00§ | –14.28§ | –10.78§ | –6.82‡ | –10.17§ | ||||
. | . | Men . | . | . | Women . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm subtype . | Total† . | White . | Black . | Asian . | White . | Black . | Asian . | ||||
| Lymphoid neoplasms, total | –0.50‡ | –0.84§ | –1.84 | –0.33 | 0.08 | 0.14 | 1.39 | ||||
| B-cell lymphoid neoplasms, total | 0.51‡ | 0.23 | –1.25 | 0.86 | 1.01§ | 0.43 | 2.11‡ | ||||
| DLBCL | –0.46§ | –0.73§ | –2.28 | –1.99 | 0.19 | 1.27 | 1.75 | ||||
| Marginal zone lymphoma | 21.31§ | 21.36§ | –∥ | 18.14‡ | 22.17§ | –∥ | 17.49‡ | ||||
| Follicular lymphoma | 0.51 | 0.10 | –1.31 | 4.48 | 1.24‡ | 0.19 | –0.05 | ||||
| CLL/SLL | –2.67§ | –2.20§ | –3.68‡ | –0.76 | –3.11§ | –1.78 | –8.99§ | ||||
| Mantle cell lymphoma | 8.08§ | 12.21§ | 5.74 | 13.67‡ | 2.02 | –∥ | –∥ | ||||
| Burkitt lymphoma/leukemia | 8.36§ | 5.47‡ | 7.95 | 17.85§ | 15.61§ | –∥ | 11.48 | ||||
| Plasma cell neoplasms | –0.73 | –0.78 | –1.86 | –2.06 | –0.67 | –1.59 | 2.79 | ||||
| Hairy cell leukemia | –1.84 | –2.77‡ | –∥ | –1.13 | 2.35 | –∥ | –∥ | ||||
| Lymphoplasmacytic lymphoma | 4.42‡ | 5.30‡ | 5.41 | 5.25 | 2.86 | –5.31 | –∥ | ||||
| Waldenström macroglobulinemia | –0.21 | 1.01 | –3.25 | –6.51 | –1.11 | –∥ | –∥ | ||||
| B-cell lymphoid neoplasms, NOS | 1.64 | 1.36 | 3.48 | –1.34 | 2.13 | 7.53 | 0.92 | ||||
| T/NK-cell lymphoid neoplasms, total | 3.80§ | 3.45§ | 1.09 | 3.73‡ | 4.32 | 6.74‡ | 1.05 | ||||
| Mycosis fungoides/Sézary syndrome | 1.11 | 1.16 | –1.73 | –5.20 | 1.32 | 6.08 | –2.09 | ||||
| Peripheral T-cell lymphoma | 6.55§ | 6.21§ | 0.77 | 5.09 | 6.15‡ | 13.53‡ | 2.24 | ||||
| T/NK-cell lymphoid neoplasms, NOS | 3.26‡ | 3.01 | 4.46 | 7.32 | 4.52 | –0.69 | 3.05 | ||||
| Lymphoblastic leukemia/lymphoma | 0.08 | –0.82 | –4.03 | 0.94 | 2.24 | 2.17 | –1.90 | ||||
| Prolymphocytic leukemia | 3.93 | 0.73 | –∥ | –∥ | 3.26 | –∥ | –∥ | ||||
| Hodgkin lymphoma | –0.49 | –0.27 | 1.18 | –0.63 | –0.52 | –3.12 | 6.61‡ | ||||
| Classical Hodgkin lymphoma | –0.60‡ | –0.41 | 0.94 | –0.41 | –0.53 | –3.89‡ | 7.00‡ | ||||
| Nodular sclerosis | 0.17 | 0.66 | 3.67 | 0.67 | –0.32 | –2.65 | 5.64 | ||||
| Mixed cellularity/lymphocyte depleted | –6.02§ | –6.09§ | –6.54‡ | –8.15 | –4.09‡ | –11.27 | 2.76 | ||||
| Classical Hodgkin lymphoma, NOS | 3.52‡ | 3.96‡ | 6.24 | –∥ | 2.89 | –1.05 | –∥ | ||||
| Nodular lymphocyte predominant Hodgkin lymphoma | 3.20 | 4.00 | 5.06 | –∥ | 0.80 | 4.61 | –∥ | ||||
| Unknown type lymphoid neoplasms | –12.41§ | –13.86§ | –11.00§ | –14.28§ | –10.78§ | –6.82‡ | –10.17§ | ||||
APC indicates annual percent change; other abbreviations are explained in Table 1.
All incidence rates are age adjusted to the 2000 United States population
The total APC is based on the incidence of lymphoid neoplasms among individuals of all races (whites, blacks, Asians, and other or unknown race)
P < .05
P < .01
Calculation of the APC was precluded by at least one annual rate of zero